Best results are achieved when Eximo® is lightly watered into the soil profile after application.įill the spray tank 1/4 full. Mix 32-64 ounces of Eximo® in sufficient volume of water and apply to an acre of turf. Regular use will temporarily lower soil bicarbonate and increase plant uptake of soil bound nutrients. Eximo® will not harm people or equipment at any concentration. Can be safe used as a tank additive for pH levels below 2pH. Eximo® carries the DfE (designed for the environment) government certification and is approved for use in any growing condition. Eximo® safely treats plants suffering from high bicarbonate water and soil growth conditions. EXIMO is environmentally safe, uses no water, and reduces down time. Regular use will also lower soil bicarbonate levels and improve soil structure. EXIMO Waterless Concrete Cleaner cleans oil stains better than pressure washing by working deep into the pores of concrete, restoring its original luster and clean appearance. Eximo® is designed to be sprayed directly onto turf to solubilize calcium and other salts. All rights reserved.Eximo® is a state of the art acid replacement soil conditioner powered by SynTech®, the world’s only synthetic acid.
The device has a high safety profile including a low risk of distal embolization.Īspiration Calcified lesions Denovo disease Distal embolization In-stent restenosis Laser Peripheral arterial disease Restenosis Solid-state laser.Ĭopyright © 2018 Elsevier Inc. The Eximo B-Laser™ is effective and safe in ablating atherosclerotic and restenotic tissue for both above and below the knee obstructive arterial disease. There was no target lesion revascularization and the patency was 96.8% by duplex ultrasound criteria at 30-day follow up. A significant improvement from baseline in ABI (0.24 ± 0.18), Rutherford category (-1.79 ± 1.22) and WIQ (0.26 ± 0.28) were noted at 1 month. Per Core lab, there was no device-related distal embolization, dissections that required additional therapy, perforation, or pseudoaneurysm.
The freedom from MAE through the 30-day follow-up period after intervention was 98.9%. This resulted in a mean reduction from baseline to post B-Laser™ of 33.6% ± 14.2% meeting the primary efficacy endpoint goal. Eximo byggs i Polen och Kabe r en av garna till fabriken och mrket. Post B-Laser™ and prior to adjunctive therapy, the mean percent stenosis at the target lesion was 52.1%. The mean percent stenosis at the target lesion as assessed by the Core lab was 85.7% ± 12.2 (femoro-popliteal 85.6 ± 12.8% tibials 86.0 ± 9.6%). Lesions were de novo (79.4%), followed by in-stent restenosis (ISR) (15.9%) and non in-stent restenosis (4.7%). Mean lesion length was 53.96 ± 43.18 mm and 26.2% had severe calcification.
Mean age was 70.5 years and 51% were males. The primary safety endpoint was freedom from major adverse events (MAEs) defined as: unplanned target limb amputation above the ankle, clinically driven target lesion revascularization (CD-TLR) and cardiovascular related death.Ī total of 97 subjects (107 lesions) were enrolled. The primary efficacy endpoint was the average reduction in residual diameter stenosis of >20% from baseline prior to any adjunctive therapy achieved by the B-Laser™ catheter alone. The study enrolled patients in the United States and Europe.
KABE EXIMO TRIAL
pivotal trial of the EXIMO B-Laser™.ĮX-PAD-03 is a prospective, single-arm, multi-center, international, open-label, clinical study. We present the results of the EX-PAD-03 U.S. Early data showed that the B-Laser™ is safe in treating a broad range of infrainguinal arterial lesions. B-Laser™ is a novel atherectomy device that uses a solid-state third harmonic pulsed Nd:YAG laser with an output of 355 nm.
0 kommentar(er)
